Yervoy (ipilimumab) Patient Information Guide
The provision of this Patient Information Guide to patients is required by the terms of the Marketing Authorisation. Please ensure that you are familiar with this material as it contains important safety information that you need to be aware of before, during and after treatment with ipilimumab. This Patient Information Guide was updated in September 2022 (administrative updates only). Changes to the material include removal of the Yervoy Patient Digital Risk Minimisation Material Platform url and addition of the Northern Ireland emc url.